ORIC Pharmaceuticals to Participate in Upcoming Investor Conferences

Rhea-AI Summary

ORIC Pharmaceuticals, a clinical stage oncology company, announced its management's participation in two key investor conferences in February 2023. The Guggenheim Healthcare Talks Oncology Day will feature a fireside chat on February 8 at 3:20 p.m. ET, followed by the Citi 2023 Virtual Oncology Leadership Summit on February 22 at 11:00 a.m. ET. Investors can access live webcasts through the company's website. ORIC is focused on developing treatments targeting mechanisms of resistance in cancer, with product candidates including ORIC-533, ORIC-114, and ORIC-944.

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that management will participate in the following investor conferences in February:

• Guggenheim Healthcare Talks Oncology Day – Participating in a fireside chat on Wednesday, February 8, 2023, at 3:20 p.m. ET.
  
  
• Citi’s 2023 Virtual Oncology Leadership Summit – Participating in a fireside chat on Wednesday, February 22, 2023, at 11:00 a.m. ET.

Live webcasts of the discussions will be available through the investor section of the company’s website at www.oricpharma.com. Replays of the webcasts will be available for 90 days following the event.

About ORIC Pharmaceuticals, Inc.

ORIC Pharmaceuticals is a clinical stage biopharmaceutical company dedicated to improving patients’ lives by Overcoming Resistance In Cancer. ORIC’s clinical stage product candidates include (1) ORIC-533, an orally bioavailable small molecule inhibitor of CD73, a key node in the adenosine pathway believed to play a central role in resistance to chemotherapy- and immunotherapy-based treatment regimens, being developed for multiple myeloma, (2) ORIC-114, a brain penetrant inhibitor designed to selectively target EGFR and HER2 with high potency against exon 20 insertion mutations, being developed across multiple genetically defined cancers, and (3) ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 (PRC2) via the EED subunit, being developed for prostate cancer. Beyond these three product candidates, ORIC is also developing multiple precision medicines targeting other hallmark cancer resistance mechanisms. ORIC has offices in South San Francisco and San Diego, California. For more information, please go to www.oricpharma.com, and follow us on Twitter or LinkedIn.

Contact:
Dominic Piscitelli, Chief Financial Officer
dominic.piscitelli@oricpharma.com
info@oricpharma.com

 

FAQ

What events will ORIC Pharmaceuticals participate in February 2023?

ORIC Pharmaceuticals will participate in the Guggenheim Healthcare Talks Oncology Day on February 8 and the Citi's 2023 Virtual Oncology Leadership Summit on February 22.

How can I watch the ORIC Pharmaceuticals investor conference webcasts?

Live webcasts of the discussions can be accessed through the investor section of ORIC Pharmaceuticals' website.

What are the main product candidates of ORIC Pharmaceuticals?

ORIC's main product candidates include ORIC-533, ORIC-114, and ORIC-944, targeting various cancer types and resistance mechanisms.

What is the focus of ORIC Pharmaceuticals?

ORIC Pharmaceuticals is dedicated to developing treatments aimed at overcoming mechanisms of therapeutic resistance in cancer.

When will the replays of ORIC Pharmaceuticals' webcasts be available?

Replays of the webcasts will be available for 90 days following each event.